EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The cGAS-STING pathway is a master regulator of OCT4 expression in persistent sarcoma cells and enhances cellular immunotherapy with NK and CIK lymphocytes

Giorgia Giordano, Alessandra Merlini, Federica Capozzi, Giulio Ferrero, Cristina Tucciarello, Shahab Majidi, Simona Comparato, Giulia Mesiano, Elisabetta Liuzzi, Federica Galvagno, Annamaria Massa, Silvia Brusco und 8 weitere

Cancer Immunology, Immunotherapy · 2025

DOI: 10.1007/s00262-025-04141-w ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, 2025. Verfasst von Giorgia Giordano und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Turin, Italy. Hauptthemen laut MEDLINE: cGAS-STING Signaling Pathway, Immunotherapy, Killer Cells, Natural, Cytokine-Induced Killer Cells. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Associazione Italiana per la Ricerca sul Cancro, PON 2014-2020 DM 1062/2021, PharmaMar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Advanced sarcomas have a poor prognosis and limited therapeutic options. Disease recurrence is caused by persistent cells that survive drug treatments. The alkylating agent trabectedin, when combined with the poly (ADP-ribose) polymerase 1 (PARP1) inhibitor olaparib, exhibits variable antitumor effects in advanced sarcomas. In this study, we demonstrate that the expression of the transcription factor OCT4 is upregulated in persistent cells that survive treatment with trabectedin and olaparib, through the cGAS-STING-IRF3-IFNβ pathway. This route also leads to the upregulation of natural killer (NK) and cytokine-induced killer (CIK) lymphocyte activating ligands. These molecular events enhance the antitumor efficacy of immunotherapy with NK and CIK cells, targeting both the bulk population and residual drug-tolerant cells. In conclusion, the activation of the cGAS-STING pathway has a double-edged effect, enriching the OCT4 + persistent cell population while increasing the expression of NK/CIK ligands. The addition of olaparib to trabectedin potentiates the cGAS-STING pathway activation and the upregulation of NKG2DLs, while simultaneously counteracting the OCT4 overexpression. Therefore, sequential treatment with trabectedin and olaparib followed by NK/CIK immunotherapy represents a promising strategy against advanced sarcomas and warrants further investigation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

cGAS-STING Signaling PathwayImmunotherapyKiller Cells, NaturalCytokine-Induced Killer CellsOctamer Transcription Factor-3SarcomaHumansCells, CulturedCoculture TechniquesCyclic Guanosine Monophosphate-Adenosine Monophosphate SynthaseSTING ProteinLigandsImmunity, CellularTrabectedinPhthalazinesPiperazinesDNA DamageTranscription, GeneticGene Expression Regulation, NeoplasticAnimalsMice

Stichwörter der Autor:innen

NK/CIK cellular immunotherapyOCT4OlaparibPersistent sarcoma cellsTrabectedincGAS-STING-IRF3-IFNβ pathway

Substanzen

cGAS protein, humanCyclic Guanosine Monophosphate-Adenosine Monophosphate SynthaseSTING1 protein, humanSTING ProteinLigandsPOU5F1 protein, humanOctamer Transcription Factor-3TrabectedinolaparibPhthalazines

Autor:innen und Institutionen

  • Department of Oncology, Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Turin, Italy.
  • Department of Clinical and Biological Sciences, University of Torino, Turin, Italy.
  • Department of Oncology, University of Torino, Turin, Italy. alessandra.merlini@unito.it.
  • Medical Oncology, San Luigi Gonzaga University Hospital, Orbassano, Turin, Italy. alessandra.merlini@unito.it.
  • Italian Institute for Genomic Medicine (IIGM), Turin, Italy.
  • Department of Oncology, University of Torino, Turin, Italy.

Förderung

  • Associazione Italiana per la Ricerca sul Cancro
  • PON 2014-2020 DM 1062/2021
  • PharmaMar
  • Fondazione Piemontese per la ricerca sul cancro
  • Fondazione per la ricerca sui tumori dell'apparato muscoloscheletrico e rari ONLUS
  • Ministero della Salute
  • Alleanza contro il cancro

Zitieren

APA

Giordano, G., Merlini, A., Capozzi, F., Ferrero, G., Tucciarello, C., Majidi, S., Comparato, S., Mesiano, G., Liuzzi, E., Galvagno, F., Massa, A., Brusco, S., Leuci, V., Riganti, C., Cutrupi, S., De Bortoli, M., D'Ambrosio, L., Sangiolo, D., Grignani, G., & Pignochino, Y. (2025). The cGAS-STING pathway is a master regulator of OCT4 expression in persistent sarcoma cells and enhances cellular immunotherapy with NK and CIK lymphocytes. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-025-04141-w

Vancouver

Giordano G, Merlini A, Capozzi F, Ferrero G, Tucciarello C, Majidi S, et al. The cGAS-STING pathway is a master regulator of OCT4 expression in persistent sarcoma cells and enhances cellular immunotherapy with NK and CIK lymphocytes. Cancer Immunology, Immunotherapy. 2025. doi:10.1007/s00262-025-04141-w

BibTeX
@article{Giordano2025,
  author = {Giordano, Giorgia and Merlini, Alessandra and Capozzi, Federica and Ferrero, Giulio and Tucciarello, Cristina and Majidi, Shahab and Comparato, Simona and Mesiano, Giulia and Liuzzi, Elisabetta and Galvagno, Federica and Massa, Annamaria and Brusco, Silvia and Leuci, Valeria and Riganti, Chiara and Cutrupi, Santina and De Bortoli, Michele and D'Ambrosio, Lorenzo and Sangiolo, Dario and Grignani, Giovanni and Pignochino, Ymera},
  title = {The cGAS-STING pathway is a master regulator of OCT4 expression in persistent sarcoma cells and enhances cellular immunotherapy with NK and CIK lymphocytes},
  journal = {Cancer Immunology, Immunotherapy},
  year = {2025},
  doi = {10.1007/s00262-025-04141-w}
}
Kostenlos starten →